MAPT and dementia: Altogether, the recent literature suggests that circulating t-tau levels may be a predictive biomarker to improve risk stratification for dementia and assess AD’s progression, help with enrollment of high-risk individuals into dementia prevention trials, be useful in addition to other blood biomarkers of neurodegeneration to determine cognitive improvements in clinical trials, and represent a useful biomarker for AD when added to CSF tau measures10,15–17.